Ipamorelin · Research brief
Hexarelin vs Ipamorelin: Research Peptide Comparison
Short answer
Hexarelin is among the most potent short-chain growth hormone secretagogues described in the peptide literature. That potency is also the single most common reason research teams weighing hexarelin vs ipamorelin end up selecting ipamorelin instead. Our team supplies both compounds to academic and private laboratories, and this is the question we field more than any other in the secretagogue category.…
Key takeaways
- Hexarelin and ipamorelin both act as GHS-R1a agonists, but only hexarelin has documented binding at the CD36 scavenger receptor.
- Ipamorelin was characterised by Raun and colleagues in 1998 as the first selective growth hormone secretagogue, releasing GH without meaningful ACTH and cortisol elevation.
- Hexarelin is a hexapeptide at roughly 887 g/mol; ipamorelin is a pentapeptide at roughly 712 g/mol, so equal milligram quantities are not equal molar quantities.
- In most hexarelin vs ipamorelin decisions outside cardiovascular research, selectivity outweighs raw GH-releasing potency because cortisol and prolactin movement contaminates the endpoint.
- GHRP-class receptor desensitisation means acute potency rankings are a poor predictor of performance in sustained repeated-administration designs.
- Neither compound is an FDA-approved drug; both are supplied for laboratory research only, with HPLC and mass spectrometry documentation available before purchase.
Hexarelin is among the most potent short-chain growth hormone secretagogues described in the peptide literature. That potency is also the single most common reason research teams weighing hexarelin vs ipamorelin end up selecting ipamorelin instead.
Our team supplies both compounds to academic and private laboratories, and this is the question we field more than any other in the secretagogue category. What follows is the working version: receptor behaviour, hormonal cross-talk, and the documentation that decides whether a result is reproducible.
Hexarelin vs Ipamorelin: what is the actual difference?
In a hexarelin vs ipamorelin comparison, hexarelin is a six-amino-acid secretagogue with high growth hormone releasing potency that also stimulates ACTH, cortisol and prolactin in published research. Ipamorelin is a five-amino-acid analog reported as the first selective secretagogue, producing a GH signal with far less cross-activation. Selectivity, not raw potency, usually decides the model.
The common oversimplification is that these two peptides are the same compound class separated only by strength. They aren't. Hexarelin engages a second binding target, CD36, that ipamorelin does not, which is why the two behave differently in cardiovascular research even when growth hormone output looks similar. This article covers the receptor and hormone profiles, how each compound behaves across repeated administration in a study design, and the purity and handling standards that separate clean data from noise.
Two peptides, two very different signalling profiles
Both compounds act on the growth hormone secretagogue receptor 1a (GHS-R1a), the same G-protein coupled receptor that the gut hormone ghrelin binds to trigger pulsatile GH release from the anterior pituitary. That shared target is where the overlap ends.
Hexarelin is a hexapeptide, six amino acids (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), with a molecular weight of roughly 887 g/mol. Ipamorelin is a pentapeptide, five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2), at roughly 712 g/mol. The extra residues in hexarelin aren't decorative. They widen its binding behaviour.
The headline distinction in every hexarelin vs ipamorelin discussion is selectivity. Raun and colleagues, publishing in the European Journal of Endocrinology in 1998, characterised ipamorelin as the first selective growth hormone secretagogue: it released GH without the meaningful ACTH and cortisol elevation seen with earlier GHRP-class peptides. Hexarelin, by contrast, is repeatedly reported to raise ACTH, cortisol and prolactin alongside GH.
Hexarelin also binds CD36, a scavenger receptor expressed on cardiac tissue and macrophages, independent of GHS-R1a. That second pathway is why hexarelin appears in cardiovascular literature that ipamorelin simply doesn't appear in. In our experience, labs that pick hexarelin deliberately are usually chasing that CD36 arm, not the GH curve.
Why selectivity usually wins inside a study design
The cortisol question isn't a safety talking point in a research context. It's a data integrity problem.
If a model is measuring body composition, nitrogen balance, collagen turnover or recovery markers, a compound that simultaneously moves cortisol and prolactin has introduced two confounding variables into the endpoint. The GH signal and the glucocorticoid signal pull in opposite directions on protein metabolism. Untangling them afterwards requires additional assays that most protocols never budgeted for. That is the quiet reason hexarelin vs ipamorelin comparisons so often resolve toward ipamorelin in non-cardiac work.
Here's the piece most comparison pages skip entirely. Receptor desensitisation timelines differ, and they differ in a way that breaks chronic-administration designs rather than acute ones. Research on GHRP-class secretagogues, hexarelin included, describes attenuation of the GH response with sustained repeated administration as GHS-R1a downregulates. A single-dose potency ranking therefore tells you almost nothing about week four of a four-week model. Teams that design around an acute potency figure frequently find their own baseline has drifted by the time they collect terminal data.
Does that make hexarelin the wrong choice? No. It makes it the wrong choice for a long-run GH endpoint, and a reasonable one for acute release studies or CD36-directed cardiac work. Selection follows the question, not the potency chart.
Purity, certificates of analysis and laboratory handling
A hexarelin vs ipamorelin decision collapses to nothing if the vial contents don't match the label. Peptides of this length are synthesised by solid-phase chemistry, and the failure modes are deletion sequences, incomplete deprotection and residual TFA, none of which are visible to the eye.
That's why every compound we synthesise is small-batch, sequence-verified, and released with a certificate of analysis showing HPLC purity and mass spectrometry confirmation of molecular weight. You can review the documentation for any catalog item on our certificates of analysis page before purchasing, which is the correct order of operations. A vial without an independent identity confirmation is an assumption, not a reagent.
Handling is the second failure point. Lyophilised peptide is hygroscopic and should be stored cold, typically at -20C for long-term stability, and allowed to reach room temperature before the seal is broken so condensation doesn't pull water into the cake. Once reconstituted with bacteriostatic water, material is refrigerated at 2-8C and protected from light and repeated freeze-thaw cycles. Ipamorelin and hexarelin are both reasonably stable lyophilised, and both degrade faster in solution.
These compounds are supplied strictly for laboratory research. They are not FDA-approved drugs, are not for human or veterinary consumption, and anyone with a question about an animal's health should talk to their veterinarian rather than reason from research literature. Our hexarelin and ipamorelin listings both carry batch documentation.
Hexarelin vs Ipamorelin: side-by-side research comparison
This table sets the two compounds against the attributes that actually change study design decisions rather than marketing copy. Read the final column first if you're narrowing a shortlist.
| Attribute | Hexarelin | Ipamorelin | Bottom line for research use |
|---|---|---|---|
| Structure and molecular weight | Hexapeptide, six amino acids, roughly 887 g/mol | Pentapeptide, five amino acids, roughly 712 g/mol | Different molar quantities per milligram, so mg-for-mg comparisons between the two are not equivalent comparisons |
| Primary receptor activity | GHS-R1a agonist, plus documented binding at the CD36 scavenger receptor | GHS-R1a agonist with no comparable CD36 activity reported | Hexarelin is the only one of the pair with a second characterised pathway, which is its main research differentiator |
| Cortisol, ACTH and prolactin | Reported to elevate ACTH, cortisol and prolactin alongside GH | Characterised in the literature as selective, with minimal effect on these hormones | Ipamorelin introduces fewer confounding endocrine variables into non-endocrine endpoints |
| Behaviour across repeated administration | GHRP-class attenuation of GH response reported with sustained repeated exposure | Generally described as better tolerated across repeated exposure in published models | Chronic-design studies more often specify ipamorelin to protect a stable baseline |
| Relative GH-releasing potency | Among the most potent short secretagogues characterised | Effective GH release, lower relative potency per unit than hexarelin | Potency is only an advantage when the acute GH spike is itself the endpoint |
| Common research context | Cardiac and CD36-directed studies, acute GH release models | Body composition, recovery, sleep architecture and longer-run GH axis models | The question being asked, not the strength ranking, should drive the selection |
What if: common laboratory scenarios
What if the lyophilised cake looks cracked, shrunken or stuck to the vial wall?
Check the certificate of analysis for that batch before assuming the material is compromised. Cake appearance varies with fill volume, lyophilisation cycle and shipping vibration, and a fractured or wall-adhered cake is frequently cosmetic rather than chemical. What appearance cannot tell you is purity or identity, which is precisely what HPLC and mass spectrometry data on the batch certificate exist to confirm. If the cake appears melted, glassy or visibly wet, that suggests a temperature excursion and the batch should be set aside.
What if a vial was left at room temperature during shipping or on the bench?
Lyophilised peptide tolerates short ambient exposure far better than reconstituted solution, which is the practical distinction that matters here. Dry powder is comparatively stable during transit, which is why research peptides ship without cold chain in most cases. Solution is different. Once reconstituted, material held outside 2-8C for an extended period, or subjected to repeated freeze-thaw cycles, can lose integrity in ways no visual check will reveal.
What if the GH response fades partway through a repeated-administration model?
Treat it as an expected receptor-level finding rather than a compound failure. GHS-R1a downregulation with sustained agonist exposure is described across the GHRP class, and hexarelin's high potency does not exempt it. This is the specific reason many chronic-design protocols specify ipamorelin, or pair a secretagogue with a GHRH analog acting on a separate receptor. Document the attenuation curve rather than discarding it, because the timing of that fade is often the most interesting data in the run.
The unglamorous truth about secretagogue comparisons
Let's be direct about this: most hexarelin vs ipamorelin content online ranks the two compounds as if one is simply a better version of the other. That framing is wrong, and it produces bad study design. Hexarelin is more potent at GHS-R1a and carries a second receptor pathway that ipamorelin lacks entirely. Ipamorelin is cleaner endocrinologically and holds up better across repeated exposure. Neither fact makes one superior. A cardiac CD36 model and a twelve-week body composition model are not competing for the same reagent, and treating them as if they are is how research teams waste a quarter.
If you're still narrowing the field, the ipamorelin research overview and our ipamorelin questions answered page cover the selective secretagogue side in more depth, while combination work is addressed in our CJC-1295 and ipamorelin blend and tesamorelin and ipamorelin stack listings. The full catalog sits in our shop, and shipping and facility details are on our location page.
The honest closing thought on hexarelin vs ipamorelin is that the comparison stops being interesting the moment you write down your actual endpoint. Potency charts feel decisive because they produce a winner, but no receptor reads a chart. GHS-R1a responds to the ligand you give it, on the schedule you give it, and the compound that produces the cleanest answer is the one whose off-target signalling doesn't overlap with the thing you're measuring. Write the endpoint first. The peptide selects itself.
References
Peer-reviewed sources on Ipamorelin indexed in PubMed, listed for research context. Real Peptides supplies Ipamorelin for laboratory research use only.
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024. PMID 39043357. doi:10.1016/j.physbeh.2024.114644
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science, 2024. PMID 38996787. doi:10.1016/j.anireprosci.2024.107550
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014. PMID 25331030. doi:10.1007/s00384-014-2030-8
- Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 2012. PMID 27186127. doi:10.2147/JEP.S35396
- Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 2009. PMID 19289567. doi:10.1124/jpet.108.149211
- Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters, 2004. PMID 15665799
- Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778. doi:10.14670/HH-17.707
- The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001. PMID 11735244. doi:10.1054/ghir.2001.0239
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA